Talabostat

Bibliography

• BACHOVCHIN WW, PLAUT AG, FLENTKE GR, LYNCH M, KETTNER CA: Inhibition of IGA1 proteinases from Neisseria gonorrhoeae and Hemophilus influenzae by peptide prolyl boronic acids. J. Biol. Chem. (1990) 265(7):3738-3743.
   PubMed Web of Science ®Google Scholar
• COUTTS SJ, KELLY TA, SNOW RJ et al.: Structure–activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of XAA-boropro dipeptides. J. Med. Chem. (1996) 39(10):2087-2094.
   PubMed Web of Science ®Google Scholar
• SCANLAN MJ, RAJ BK, CALVO B et al.: Molecular cloning of fibroblast activation protein α, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. USA (1994) 91(12):5657-5661.
   PubMed Web of Science ®Google Scholar
• LYNN KR: The isolation and some properties of dipeptidyl peptidases II and III from porcine spleen. Int. J. Biochem. (1991) 23(1):47-50.
   PubMedGoogle Scholar
• UNDERWOOD R, CHIRAVURI M, LEE H et al.: Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J. Biol. Chem. (1999) 274(48):34053-34058.
   PubMed Web of Science ®Google Scholar
• JONES B, ADAMS S: Characterization of innate effector cells involved in the anti-tumor activity of talabostat (PT-100). AACR Meeting Abstr. (2006) 2006(1):1094-B.
   Google Scholar
• ADAMS S, MILLER G, JONES B: T-cell independent anti-tumor activity of talabostat (PT-100) as a single agent and in combination with chemotherapy in mice. AACR Meeting Abstr. (2005) 2005(1):153-A.
   Google Scholar
• ADAMS S, MILLER GT, JESSON MI et al.: PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. (2004) 64(15):5471-5480.
   PubMed Web of Science ®Google Scholar
• UPRICHARD MJ, JONES B: Phase I rising multiple-dose study of talabostat (PT-100) in healthy subjects. ASH Ann. Meeting Abstr. (2004) 104(11):4215.
   Google Scholar
• NEMUNAITIS J, VUKELJA SJ, RICHARDS D et al.: Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy. Cancer Investig. (2006) 24(6):553-561.
   PubMed Web of Science ®Google Scholar
• AL-KATIB A, HURD DD, RAJU R et al.: Phase I study of talabostat and rituximab in patients with indolent non-Hodgkin's lymphoma with primary resistance to or progression following rituximab. ASH Annu. Meeting Abstr. (2004) 104(11):1403.
   Google Scholar
• REDMAN BG, ERNSTOFF MS, GAJEWSKI TF et al.: Phase II trial of talabostat in stage IV melanoma. ASCO Meeting Abstr. (2005) 23(16 Suppl.):7570.
   Google Scholar
• UPRICHARD MJ, O'DAY SJ, PAVLICK AC et al.: Phase II study of talabostat and cisplatin in stage IV melanoma. ASCO Meeting Abstr. (2005) 23(16 Suppl.):7563.
   Google Scholar
• CUNNINGHAM C, PAVLICK AC, KHAN KD et al.: Phase II trial of talabostat and cisplatin in patients with stage IV melanoma. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(18 Suppl.):8040.
   Google Scholar
• CUNNINGHAM C, RICHARDS D, SALGIA R et al.: Phase II trial of talabostat and docetaxel in patients with stage IIIB/IV NSCLC. ASCO Meeting Abstr. (2005) 23(16 Suppl.):7120.
   Google Scholar
• KHAN KD, O'BRIEN S, RAI KR et al.: Phase II study of talabostat and rituximab in fludarabine/rituximab-resistant or refractory patients with CLL. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(18 Suppl.):6598.
   Google Scholar
• KOUKOURAKIS MI, GIATROMANOLAKI A, HARRIS AL, SIVRIDIS E: Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. (2006) 66(2):632-637.
   PubMed Web of Science ®Google Scholar
• RETTIG WJ, GARIN-CHESA P, HEALEY JH et al.: Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. (1993) 53(14):3327-3335.
   PubMed Web of Science ®Google Scholar
• GARIN-CHESA P, OLD LJ, RETTIG WJ: Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. USA (1990) 87(18):7235-7239.
   PubMed Web of Science ®Google Scholar
• PARK JE, LENTER MC, ZIMMERMANN RN et al.: Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. (1999) 274(51):36505-36512.
   PubMed Web of Science ®Google Scholar
• NIEDERMEYER J, ENENKEL B, PARK JE et al.: Mouse fibroblast-activation protein-conserved Fap gene organization and biochemical function as a serine protease. Eur. J. Biochem. (1998) 254(3):650-654.
   PubMedGoogle Scholar
• NIEDERMEYER J, GARIN-CHESA P, KRIZ M et al.: Expression of the fibroblast activation protein during mouse embryo development. Int. J. Dev. Biol. (2001) 45(2):445-447.
   PubMed Web of Science ®Google Scholar
• BROWN DD, WANG Z, FURLOW JD et al.: The thyroid hormone-induced tail resorption program during xenopus laevis metamorphosis. Proc. Natl. Acad. Sci. USA (1996) 93(5):1924-1929.
   PubMed Web of Science ®Google Scholar
• RETTIG WJ, SU SL, FORTUNATO SR et al.: Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int. J. Cancer (1994) 58(3):385-392.
   PubMed Web of Science ®Google Scholar
• KONG FM, ANSCHER MS, MURASE T et al.: Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann. Surg. (1995) 222(2):155-162.
   PubMed Web of Science ®Google Scholar
• NIEDERMEYER J, KRIZ M, HILBERG F et al.: Targeted disruption of mouse fibroblast activation protein. Mol. Cell Biol. (2000) 20(3):1089-1094.
   PubMed Web of Science ®Google Scholar
• CHENG JD, DUNBRACK RL Jr, VALIANOU M et al.: Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. (2002) 62(16):4767-4772.
   PubMed Web of Science ®Google Scholar
• CHENG JD, VALIANOU M, CANUTESCU AA et al.: Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol. Cancer Ther. (2005) 4(3):351-360.
   PubMed Web of Science ®Google Scholar
• MERSMANN M, SCHMIDT A, RIPPMANN JF et al.: Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas. Int. J. Cancer (2001) 92(2):240-248.
   PubMed Web of Science ®Google Scholar
• SCHMIDT A, MULLER D, MERSMANN M et al.: Generation of human high-affinity antibodies specific for the fibroblast activation protein by guided selection. Eur. J. Biochem. (2001) 268(6):1730-1738.
   PubMedGoogle Scholar
• VON BONIN A, HUHN J, FLEISCHER B: Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway. Immunol. Rev. (1998) 161:43-53.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, STERMAN D, JABLONS D et al.: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl. Cancer Inst. (2004) 96(4):326-331.
   PubMed Web of Science ®Google Scholar
• O'ROURKE MG, SCHMIDT CW, O'ROURKE TR, ELLEM KA: Immunotherapy, including gene therapy, for metastatic melanoma. Aust. NZ J. Surg. (1997) 67(12):834-841.
   PubMedGoogle Scholar
• BARRIO MM, DE MOTTA PT, KAPLAN J et al.: A Phase I study of an allogeneic cell vaccine (vaccimel) with GM-CSF in melanoma patients. J. Immunother. (2006) 29(4):444-454.
   PubMed Web of Science ®Google Scholar
• HABAL N, GUPTA RK, BILCHIK AJ et al.: Cancervax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann. Surg. Oncol. (2001) 8(5):389-401.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, JAHAN T, ROSS H et al.: Phase I/II trial of autologous tumor mixed with an allogeneic gvax vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. (2006) 13(6):555-562.
   PubMed Web of Science ®Google Scholar
• SIMONS JW, SACKS N: Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the gvax(R) vaccine for prostate cancer. Urol. Oncol. (2006) 24(5):419-424.
   PubMed Web of Science ®Google Scholar